Prenetics Global Raises Annual Revenue Guidance Following Strong Q2 Growth

Key Facts

1Prenetics Global reported Q2 revenue of $46.5 million, up 29% sequentially.

2The company achieved its first month of positive consolidated adjusted free cash flow in July 2026.

3The company raised its full-year revenue outlook driven by the scaling of its IM8 supplement business.

In a move reflecting the successful expansion into the consumer health sector, Prenetics Global announced strong financial results for the second quarter of 2026. The company reported revenue of $46.5 million, representing a 29% increase compared to the previous quarter. This performance was primarily driven by the rapid scaling of the IM8 supplement business and improved marketing efficiency, supported by a financing facility from General Catalyst.

According to reports, the company achieved a significant financial milestone in July 2026 by recording its first month of positive consolidated adjusted free cash flow. Based on this operational momentum, management has raised its full-year revenue outlook, citing the continued growth of the supplement division. Analysts suggest that this shift toward cash flow positivity and accelerated growth strengthens confidence in the company's business model within the biotech and health sectors.

Looking ahead, investors are monitoring the sustainability of the positive cash flows that began last July as a catalyst for stock stability. In the absence of updated price data for the PRE ticker, outlooks remain tied to the company's ability to meet its revised 2026 fiscal year revenue targets. Global markets also await key economic data that may influence risk appetite in the small-cap sector, including upcoming inflation and growth reports in the coming weeks.

Sources:

marketbeat.com